Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
MONTREAL — Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem.
Article content
Article content
The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028.
Article content
Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment.
Article content
Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts.
Article content
'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics.
Article content
'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group.
Article content
'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal.
Article content
About Ability Biotherapeutics
Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. www.ability.bio
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
6 minutes ago
- Winnipeg Free Press
Google to pay $36M fine for anticompetitive deals with Australia's largest telcos
MELBOURNE, Austalia (AP) — Google has agreed to pay a 55 million Australian dollar ($36 million) fine for signing anticompetitive deals with Australia's two largest telcos that banned the installation of competing search engines on some smartphones, the U.S. tech giant and Australia's competition watchdog said. The Australian Competition and Consumer Commission said in a statement it had commenced proceedings in the Australian Federal Court on Monday against the Singapore-based Google Asia Pacific division. The court will decide whether the AU$50 million ($36 million) penalty is appropriate. Under the anticompetitive agreements, which were in place for 15 months until March 2021, Telstra and Optus only pre-installed Google Search on Android phones sold to customers. Other search engines were excluded. In return, the telcos received a share of the advertisement revenue Google generated from those customers. Google accepted that the agreements were likely to have the effect of 'substantially lessening competition,' the commission said. Google has also signed a court-enforceable undertaking that commits the company to removing certain pre-installation and default search engine restrictions from its contracts with Android phone manufacturers and telcos, the commission said. The tech company said in a statement: 'We're pleased to resolve the ACCC's concerns, which involved provisions that haven't been in our commercial agreements for some time.' Commissioner chair Gina-Cass Gottlieb said: 'Conduct that restricts competition is illegal in Australia because it usually means less choice, higher costs or worse service for consumers.' Monday Mornings The latest local business news and a lookahead to the coming week. 'Importantly, these changes come at a time when AI search tools are revolutionising how we search for information, creating new competition,' Cass-Gottlieb added. Last year, Telstra, Optus and their smaller rival TPG agreed to court-enforceable undertakings with the commission that they would not renew or make similar deals with Google to limit search options.
Cision Canada
an hour ago
- Cision Canada
KuCoin Spotlight Drives AI Gaming Innovation: Launches Token Sale for AKEDO with Early Access, Exclusive Benefits, and Principal Protection
PROVIDENCIALES, Turks and Caicos Islands, Aug. 18, 2025 /CNW/ -- KuCoin, a leading global cryptocurrency exchange, is thrilled to announce the launch of its latest Spotlight token sale featuring AKEDO (AKE). This move highlights KuCoin's commitment to advancing groundbreaking Web3 innovations, especially where artificial intelligence, gaming, and blockchain converge. Founded in 2024 and based in Zug, Switzerland, AKEDO is a trailblazing multi-agent AI framework that transforms Web3 gaming with autonomous content creation and smart collaboration. As the first platform to embed AI agents directly into game engines, it lets users craft studio-quality games in minutes using simple natural language prompts—no coding skills needed—and does so 100 times faster and more affordably than traditional large language models. Starting as a Telegram-based "tap-to-earn" game called Akedog, AKEDO has grown into a full ecosystem that democratizes GameFi, merging user-generated content with on-chain ownership and genuine crypto rewards, akin to "TikTok meets Roblox" on the blockchain. Its cutting-edge setup spans multiple chains, including Solana (home to the AKE token), TON, BNB, Bera, and DuckChain, enabling earnings in $DOGE, $BNB, $USDT, and more through the "PlayDrop" feature. Via KuCoin Spotlight, users get early access to the AKE token sale, enabling investment in this game-changing project ahead of public listing. Key perks include: Securing tokens at a reduced price, with the Spotlight Fully Diluted Valuation (FDV) at 80% of the prior financing round, plus a 10% extra discount for KCS subscriptions. Guaranteed inclusion for everyone via over-subscription with proportional allocation, ensuring all participants get a share. Enhanced protection through a principal protection buyback, with details in the official announcement. Renowned for upgrades like a fresh UI, dual-crypto support, and staking perks, the Spotlight program keeps championing ventures that fuel innovation and empower users. For participation details, please visit the event landing page.
Vancouver Sun
3 hours ago
- Vancouver Sun
Air Canada strikers dig in against order: 'Can't fire us all'
(Bloomberg) — An Air Canada union wants to 'dismantle' a process the government is using to end strikes, a representative said after flight attendants defied an order to return to work on Sunday. 'If we stick together, they can't fire us all,' Wesley Lesosky, president of the Air Canada Component of the Canadian Union of Public Employees that represents more than 10,000 cabin crew, said in a public video call late on Sunday. 'The large national union behind us is fully supporting us for our cause, fully supporting the dismantling of the 107 process.' That's a reference to Section 107, the legal clause the government used to try and stop a walkout over pay which froze operations at Canada's largest airline. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. The strike since Saturday disrupts a crucial mode of transport for some communities across the world's second-largest country by area. The company estimated some 130,000 passengers a day were affected during the peak summer holiday season. On Saturday, the labor minister directed the independent Canada Industrial Relations Board to order the company and workers to resume operations, extend their collective agreement and impose binding arbitration to reach a new deal. The union defied that order to go back to work by 2 p.m. Sunday, forcing Air Canada to delay a plan to restart operations during the weekend. The Montreal-based carrier now plans to resume operations 4 p.m. Toronto time Monday, Lesosky said. Read: Air Canada Delays Resuming Flights as Strikers Defy Stop Order On Sunday night it was not clear how the labor board, government or company would seek to enforce the order. A hearing about whether the action is an illegal strike was being heard in front of the CIRB on Sunday night, Lesosky said. The labor board could determine this during the hearing itself, a union spokesman said by phone. 'We are here ready to bargain,' Lesosky said, adding that there's no agreement with the company on so-called ground pay, a key part of the dispute because attendants are currently only paid once planes are in the air. 'We're not willing to accept binding arbitration ordered and rammed down our throat,' he said. 'Our priority is our passengers and we regret very deeply the impact this illegal labor action is having on them,' an Air Canada spokesman said. The CIRB did not respond to a request for comment.
